FDA approves new drug for pancreatic cancer

On Oct. 22, the U.S. Food and Drug Administration (FDA) approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with metastatic pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here